Dupilumab improves lung function in patients with uncontrolled, moderate-to-severe asthma Source: ERJ Open Res, 6 (1) 00204-2019; 10.1183/23120541.00204-2019 Year: 2020
Dupilumab improves lung function and reduces severe exacerbations in uncontrolled persistent asthma patients with high and low reversibility Source: International Congress 2017 – Evolution or revolution in the treatment of asthma and allergies Year: 2017
Both moderate and severe exacerbations accelerate physical activity decline in COPD patients Source: Eur Respir J, 51 (1) 1702110; 10.1183/13993003.02110-2017 Year: 2018
Differences in vessel endothelium function in severe COPD and severe asthma patients Source: Eur Respir J 2006; 28: Suppl. 50, 404s Year: 2006
A high degree of dyspnea is associated with poor exercise capacity in COPD patients, airflow obstruction being equal Source: International Congress 2018 – What’s new in lung function and exercise assessment in COPD? Year: 2018
Correlation between respiratory muscles function, systemic inflammation and dyspnoea in patients with severe COPD Source: Annual Congress 2009 - Respiratory mechanics, tissue and cell dysfunction in pulmonary disease Year: 2009
Static hyperinflation and respiratory disability were associated with frequent-exacerbation phenotype in patients with severe COPD Source: International Congress 2016 – Exploring mechanisms in health and disease Year: 2016
Pulmonary volumes change more largely than respiratory flows in COPD patients during severe acute exacerbations Source: Eur Respir J 2005; 26: Suppl. 49, 362s Year: 2005
Risk of COPD with obstruction in active smokers with normal spirometry and reduced diffusion capacity Source: Eur Respir J 2015; 46: 1589-1597 Year: 2015
Dupilumab improves lung function and reduces severe exacerbations in uncontrolled persistent asthma patients with ongoing allergic rhinitis Source: International Congress 2017 – Asthma and allergy: from the bench to the bedside Year: 2017
Effect of dupilumab on severe exacerbations in asthma patients with and without lung function improvements Source: Virtual Congress 2020 – Monoclonal antibodies; randomised controlled trials and real-world studies in asthma Year: 2020
Does inflammation decrease after recovery from severe exacerbation of COPD? Source: Eur Respir J 2005; 26: Suppl. 49, 53s Year: 2005
Impact of moderate and severe exacerbations in severe COPD patients Source: International Congress 2018 – How far are we in terms of predicting mortality and exacerbations in COPD? Year: 2018
Markers of systemic inflammation are associated with increased symptoms and respiratory exacerbations among smokers with preserved spirometry in SPIROMICS Source: International Congress 2018 – Biomarkers in COPD and asthma Year: 2018
Mild improvement in symptoms and pulmonary function in a long-term follow-up of patients with TDI-induced asthma Source: Eur Respir J 2005; 26: Suppl. 49, 604s Year: 2005
Dynamic pathophysiology in stable COPD patients with severely reduced exercise capacity Source: Annual Congress 2011 - Exercise assessment in different diseases Year: 2011
Mild parenchymal lung disease and/or low diffusion capacity impacts survival and treatment response in patients diagnosed with idiopathic pulmonary arterial hypertension Source: Eur Respir J, 55 (6) 2000041; 10.1183/13993003.00041-2020 Year: 2020
Mild parenchymal lung disease and/or low diffusion capacity impacts survival and treatment response in patients diagnosed with idiopathic pulmonary arterial hypertension Source: Virtual Congress 2020 – Pulmonary hypertension in lung diseases Year: 2020
Changes in functional capacity after endoscopic lung volume reduction in patients with chronic obstructive lung disease and severe emphysema Source: International Congress 2018 – Endoscopic lung volume reduction Year: 2018
Ability for dynamic hyperinflation increases after bronchoscopic lung volume reduction in patients with severe emphysema. Source: International Congress 2017 – Endoscopic lung volume reduction (EVLR) and targeted lung denervation (TLD) Year: 2017